You are here: Industry Insights > Market News > Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

expresspharmaDecember 04, 2020

Tag: INOVIO , kaneka , COVID-19 vaccine

Favorites

Japan’s Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals’ COVID-19 vaccine candidate, informed the company.

It did not disclose the terms of the agreement with Kaneka Eurogentec, a unit of the Japanese chemical company.

Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others, to increase the supply of the vaccine, which entered a mid-stage study last month.

The Phase 3 of the mid-to-late stage study is under a partial hold by the US Food and Drug Administration as it seeks more information, including details on a delivery device used to inject genetic material into cells.

Previous:Solutions For Powder Properties in Pharmaceuticals: Visit Micromeritics and Freeman technology in CPhI China 2020

Next:Indian pharma: Driving excellence in quality and patient centricity

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>